REYON Pharmaceutical Co., Ltd. (KRX:102460)

REYON Pharmaceutical Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 13, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	209,087	197,716	235,498	303,360	384,347	631,111
Market Cap Growth	4.40%	-16.04%	-22.37%	-21.07%	-39.10%	61.64%
Enterprise Value	418,421	403,416	381,553	498,164	550,681	726,725
Last Close Price	11400.00	10780.00	12840.00	16540.00	21444.72	34972.84
PE Ratio	-	-	56.73	84.66	52.23	116.61
PS Ratio	1.43	1.36	1.59	2.01	2.50	4.42
PB Ratio	0.95	0.90	0.94	1.22	1.55	2.57
P/TBV Ratio	0.96	0.90	0.95	1.23	1.56	2.59
P/OCF Ratio	143.54	135.73	-	35.09	44.03	54.01
EV/Sales Ratio	2.87	2.76	2.57	3.30	3.58	5.09
EV/EBITDA Ratio	217.93	1736.25	71.21	76.00	61.31	117.02
EV/EBIT Ratio	-	-	-	281.00	123.81	470.45
Debt / Equity Ratio	0.98	0.98	0.82	0.91	0.85	0.85
Debt / EBITDA Ratio	930.13	930.13	38.08	34.33	23.40	33.38
Net Debt / Equity Ratio	0.95	0.95	0.78	0.81	0.70	0.45
Net Debt / EBITDA Ratio	900.94	900.94	36.18	30.64	19.39	17.69
Net Debt / FCF Ratio	-32.41	-32.41	-11.11	-9.93	-3.20	-1.04
Asset Turnover	0.30	0.30	0.30	0.31	0.32	0.36
Inventory Turnover	2.72	2.72	1.99	2.25	2.60	2.35
Quick Ratio	0.29	0.29	0.35	0.51	1.63	2.91
Current Ratio	0.56	0.56	0.66	0.80	2.27	3.47
Return on Equity (ROE)	-12.60%	-12.60%	1.67%	1.44%	3.02%	2.33%
Return on Assets (ROA)	-4.09%	-4.09%	-0.12%	0.22%	0.58%	0.24%
Return on Invested Capital (ROIC)	-7.27%	-7.23%	-0.18%	0.36%	1.15%	0.49%
Return on Capital Employed (ROCE)	-9.80%	-9.80%	-0.30%	0.50%	1.00%	0.40%
Earnings Yield	-14.17%	-14.99%	1.76%	1.18%	1.93%	0.88%
FCF Yield	-3.09%	-3.27%	-7.41%	-6.67%	-14.16%	-16.68%
Dividend Yield	-	-	-	0.91%	0.70%	0.71%
Payout Ratio	-	-	66.27%	76.41%	61.38%	62.56%
Buyback Yield / Dilution	0.17%	0.17%	-0.15%	-0.46%	-3.03%	-4.05%
Total Shareholder Return	0.17%	0.17%	-0.15%	0.45%	-2.33%	-3.34%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.